NASDAQ:CNMD - CONMED Stock Price, News, Headlines & Rumors

CONMED trades on the NASDAQ under the ticker symbol "CNMD."

CONMED announced a quarterly dividend on Tuesday, August 14th. Investors of record on Friday, September 14th will be given a dividend of $0.20 per share on Monday, October 8th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 1.03%. The ex-dividend date of this dividend is Thursday, September 13th. View CONMED's Dividend History.

CONMED Co. (NASDAQ:CNMD) announced its quarterly earnings data on Wednesday, August, 1st. The medical technology company reported $0.46 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.45 by $0.01. The medical technology company earned $212.80 million during the quarter, compared to analysts' expectations of $207.12 million. CONMED had a net margin of 8.85% and a return on equity of 9.51%. The firm's revenue was up 7.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.41 earnings per share. View CONMED's Earnings History.

CONMED is scheduled to release their next quarterly earnings announcement on Thursday, November, 1st 2018. View Earnings Estimates for CONMED.

CONMED updated its FY18 earnings guidance on Wednesday, August, 1st. The company provided earnings per share guidance of $2.15-2.20 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.17.

3 brokerages have issued 12 month price targets for CONMED's stock. Their predictions range from $46.00 to $83.00. On average, they expect CONMED's share price to reach $64.50 in the next year. This suggests that the stock has a possible downside of 17.0%. View Analyst Price Targets for CONMED.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CONMED in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for CONMED.

Some companies that are related to CONMED include LivaNova (LIVN), Masimo (MASI), GETINGE AB/ADR (GNGBY), NxStage Medical (NXTM), AxoGen, Inc Common Stock (AXGN), Natus Medical (BABY), Viewray (VRAY), Cutera (CUTR), electroCore (ECOR), BioLife Solutions (BLFS), Rockwell Medical (RMTI), Vision Sciences (CGNT), Helius Medical Technologies (HSDT), Fonar (FONR) and Semler Scientific (SMLR).

Media coverage about CNMD stock has been trending somewhat positive recently, according to Accern Sentiment. The research firm ranks the sentiment of press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. CONMED earned a media and rumor sentiment score of 0.03 on Accern's scale. They also gave headlines about the medical technology company an impact score of 45.47 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days. View Recent Headlines for CONMED.

CONMED's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (13.37%), Dimensional Fund Advisors LP (6.70%), SCOPIA CAPITAL MANAGEMENT LP (6.60%), Scopia Capital Management LP (6.13%), Victory Capital Management Inc. (4.32%) and Macquarie Group Ltd. (2.77%). Company insiders that own CONMED stock include Charles Farkas, Curt R Hartman, Daniel Jonas, Dirk Kuyper, Heather L Cohen, Jo Ann Golden, Luke A Pomilio, Mark E Tryniski, Nathan Folkert and Terence M Berge. View Institutional Ownership Trends for CONMED.

CNMD stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Scopia Capital Management LP, Dimensional Fund Advisors LP, Epoch Investment Partners Inc., Millennium Management LLC, United Services Automobile Association, Huber Capital Management LLC and Fisher Asset Management LLC. Company insiders that have sold CONMED company stock in the last year include Daniel Jonas, Jo Ann Golden, Luke A Pomilio, Nathan Folkert and Terence M Berge. View Insider Buying and Selling for CONMED.

CNMD stock was purchased by a variety of institutional investors in the last quarter, including Hood River Capital Management LLC, FMR LLC, BlackRock Inc., Citadel Advisors LLC, American Century Companies Inc., Granahan Investment Management Inc. MA, Bank of Montreal Can and First Trust Advisors LP. Company insiders that have bought CONMED stock in the last two years include Charles Farkas, Curt R Hartman, Heather L Cohen and Mark E Tryniski. View Insider Buying and Selling for CONMED.

Shares of CNMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CNMD stock can currently be purchased for approximately $77.71.

CONMED has a market capitalization of $2.15 billion and generates $796.39 million in revenue each year. The medical technology company earns $55.48 million in net income (profit) each year or $1.89 on an earnings per share basis. CONMED employs 3,100 workers across the globe.

CONMED's mailing address is 525 FRENCH ROAD, UTICA NY, 13502. The medical technology company can be reached via phone at 315-624-3215.